Semaglutide As a Multiorgan Therapeutic Agent: Evidence for Cardiovascular, Renal, and Hepatic Benefits

Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), is being used as a cardiometabolic treatment instead of a medication to reduce blood sugar. Major adverse cardiovascular events have decreased, diabetic kidney disease has progressed more slowly, obesity-related heart failure with preserved ejection fraction (HFpEF) symptoms have improved, and metabolic dysfunction-associated steatohepatitis (MASH) has improved histologically, according to large randomized trials. The pharmacology, suggested mechanisms, important clinical data, and safety profile of semaglutide across several organ systems are summarized in this review, which also identifies any gaps. Keywords: Semaglutide; GLP-1 receptor agonist; cardiovascular outcomes; chronic kidney disease; MASH; safety; pharmacovigilance